588|1949|Public
25|$|According to Canadian Food and Drug Regulations, wine in Canada is an {{alcoholic}} beverage that {{is produced by}} the complete or partial alcoholic fermentation of fresh grapes, grape must, products derived solely from fresh grapes, or any combination of them. There are many materials added {{during the course of}} the manufacture, such as yeast, concentrated grape juice, dextrose, fructose, glucose or glucose solids, invert sugar, sugar, or aqueous solutions. Calcium sulphate in such quantity that the content of soluble sulphates in the finished wine shall not exceed 0.2 per cent weight by volume calculated as potassium sulphate. Calcium carbonate in such quantity that the content of tartaric acid in the finished wine shall not be less than 0.15 per cent weight by volume. Also, sulphurous acid, including salts thereof, in such quantity that its content in the finished wine shall not exceed 70 parts per million in the free state, or 350 parts per million in the combined state, calculated as sulphur dioxide. Caramel, amylase and pectinase at a maximum level of use consistent with <b>good</b> <b>manufacturing</b> <b>practice.</b> Brandy, fruit spirit or alcohol derived from the alcoholic fermentation of a food source distilled to not less than 94 per cent alcohol by volume. Prior to final filtration may be treated with a strongly acid cation exchange resin in the sodium ion form, or a weakly basic anion exchange resin in the hydroxyl ion form.|$|E
500|$|... "Hop extract" [...] {{means an}} extract derived from hops {{by a process}} {{employing}} the solvent. The hop extract should not contain more than 2.2 per cent of the solvent used. The solvent listed on Canada’s Food and Drug Regulations website are hexane, methanol, or methylene chloride. Furthermore, carbon dioxide or ethyl alcohol {{should be kept in}} an amount consistent with <b>good</b> <b>manufacturing</b> <b>practice.</b>|$|E
2500|$|Pharmaceutical fraud {{involves}} deceptions which bring {{financial gain}} to a pharmaceutical company. It affects individuals and {{public and private}} insurers. There are several different schemes used to defraud {{the health care system}} which are particular to the pharmaceutical industry. These include: <b>Good</b> <b>Manufacturing</b> <b>Practice</b> (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. Of this amount $2.5 billion was recovered through False Claims Act cases in FY 2010. Examples of fraud cases include the GlaxoSmithKline $3 billion settlement, Pfizer $2.3 billion settlement and Merck & Co. $650 million settlement. Damages from fraud can be recovered by use of the False Claims Act, most commonly under the qui tam provisions which rewards an individual for being a [...] "whistleblower", or relator (law).|$|E
50|$|Volume 4 - <b>Good</b> <b>Manufacturing</b> <b>Practices.</b>|$|R
30|$|Rulebook on <b>Good</b> <b>Manufacturing</b> <b>Practices</b> (fully in a {{compliance}} with EudraLex Volume 4 <b>Good</b> <b>Manufacturing</b> <b>Practices</b> Annex 1 for Manufacture of Sterile Medicinal Products 01 /fully 03 / 2009, Annex 3 for Manufacture of Radiopharmaceuticals, Annex 11 for Computerized Systems and Annex 15 for Qualification and validation.|$|R
2500|$|Special quality {{assurance}} needs, <b>good</b> <b>manufacturing</b> <b>practices,</b> validation protocols, etc ...|$|R
2500|$|In 2001, Lilly filed a New Drug Application (NDA) for {{duloxetine}} {{with the}} US Food and Drug Administration. However, in 2003, the FDA [...] "recommended this application as not approvable from the manufacturing and control standpoint" [...] because of [...] "significant cGMP (current <b>Good</b> <b>Manufacturing</b> <b>Practice)</b> violations at {{the finished product}} manufacturing facility" [...] of Eli Lilly in Indianapolis. Additionally, [...] "potential liver toxicity" [...] and QTc interval prolongation appeared as a concern. The FDA experts concluded that [...] "duloxetine can cause hepatotoxicity {{in the form of}} transaminase elevations. It may also be a factor in causing more severe liver injury, but there are no cases in the NDA database that clearly demonstrate this. Use of duloxetine in the presence of ethanol may potentiate the deleterious effect of ethanol on the liver." [...] The FDA also recommended [...] "routine blood pressure monitoring" [...] at the new highest recommended dose of 120mg, [...] "where 24% patients had one or more blood pressure readings of 140/90 vs. 9% of placebo patients." ...|$|E
5000|$|Investigational {{products}} maintain <b>Good</b> <b>Manufacturing</b> <b>Practice</b> in storage, {{manufacturing and}} handling.|$|E
5000|$|Set high {{standards}} in safety, <b>good</b> <b>manufacturing</b> <b>practice</b> and {{on environmental issues}} ...|$|E
40|$|Quality {{assurance}} of pharmaceuticals A compendium of guidelines and related materials Volume 2, 2 nd updated edition <b>Good</b> <b>manufacturing</b> <b>practices</b> and inspectionWHO Library Cataloguing-in-Publication Data Quality {{assurance of}} pharmaceuticals: {{a compendium of}} guidelines and related materials. Vol. 2, <b>Good</b> <b>manufacturing</b> <b>practices</b> and inspection. – 2 nd ed. 1. Drug and narcotic control – standards 2. Drug industry – standards 3. Pharmaceutical preparations – standards 4. Biological products – standard...|$|R
50|$|Bottled {{water is}} {{regulated}} by the Food & Drug Administration according to standards of identity, standards of quality and <b>good</b> <b>manufacturing</b> <b>practices.</b>|$|R
5000|$|Myprotein {{achieved}} ISO9001 production {{certification in}} 2007 [...] and also have GMP (<b>Goods</b> <b>Manufacturing</b> <b>Practice)</b> and HACCP (Hazard Analysis Critical Control Points) accreditations.|$|R
5000|$|They are [...] "exempt from <b>good</b> <b>manufacturing</b> <b>practice</b> {{requirements}} {{related to}} expiration dating".|$|E
50|$|Involve fraud {{with the}} <b>Good</b> <b>Manufacturing</b> <b>Practice</b> (GMP) Regulations which require {{manufacturers}} to have adequately equipped manufacturing facilities, adequately trained personnel, stringent {{control over the}} manufacturing process, appropriate laboratory controls, complete and accurate records, reports, appropriate finished product examination, and so on. Certain violations of the <b>Good</b> <b>Manufacturing</b> <b>Practice</b> Regulations may {{be the basis for}} a False Claims Act lawsuit.|$|E
50|$|Documentation is a {{critical}} tool for ensuring GxP adherence. For more information, see <b>good</b> <b>manufacturing</b> <b>practice.</b>|$|E
50|$|All {{aspects of}} food production, {{including}} packaging, are tightly controlled and have regulatory requirements. Uniformity, cleanliness and other requirements {{are needed to}} maintain <b>Good</b> <b>Manufacturing</b> <b>Practices.</b>|$|R
5000|$|Dassant {{baking mixes}} are kosher certified. [...] The {{manufacturing}} facility is routinely inspected by a 3rd party auditor and adheres to FDA regulations and <b>Good</b> <b>Manufacturing</b> <b>Practices.</b>|$|R
5000|$|H.R. 5620, {{a bill to}} {{establish}} minimum standards for <b>good</b> <b>manufacturing</b> <b>practices</b> for the minimal processing of produce, including sanitation and water standards, introduced March 13, 2008 ...|$|R
50|$|In addition, {{companies}} {{can take advantage}} of existing scenario based tools and should follow <b>Good</b> <b>Manufacturing</b> <b>Practice</b> guidelines.|$|E
50|$|Manufacturing {{protocols}} {{are required}} by current <b>good</b> <b>manufacturing</b> <b>practice</b> (cGMP) for manufacture of foods, pharmaceuticals, and medical devices.|$|E
50|$|The Institute has {{struggled}} to implement <b>Good</b> <b>manufacturing</b> <b>practice</b> (GMP) as mandated by World Health Organization (WHO) requirements.|$|E
40|$|Abstract: International {{concerns}} over food safety have accelerated the evolution {{and implementation of}} HACCP and risk assessment. Risk assessment and HACCP are constituents of the overall risk analysis process. Risk analysis includes risk management and risk communication in addition to risk assessment. Risk assessment is an integral constituent of the series of activities that starts with <b>Good</b> <b>Manufacturing</b> <b>Practices</b> and culminates in microbiological criteria used {{for the management of}} microbial hazards for food in international trade. <b>Good</b> <b>Manufacturing</b> <b>Practices</b> (GMP’s) or <b>Good</b> Hygienic Practices (GHP’s) address the possible contamination or adulteration o...|$|R
50|$|The CRIUM, Hyderabad {{has been}} awarded the ISO 9001:2008 certification. The {{pharmacy}} at the institute has a <b>Good</b> <b>Manufacturing</b> <b>Practices</b> (GMP) certificate for manufacture of research and other drugs.|$|R
50|$|<b>Good</b> <b>Manufacturing</b> <b>Practices</b> (GMP): The {{facilities}} include {{of various}} suites for drug production such as dispensary, mixing and blending, granulation, compression (tableting), capsulation, tablet coating, and solutions & suspension preparation.|$|R
5000|$|Auditing of {{manufacturers}} {{to ensure they}} conform to <b>Good</b> <b>Manufacturing</b> <b>Practice</b> (GMP) and have a suitable Quality Management System (QMS) ...|$|E
50|$|Herbal {{medicines}} must be now manufactured under <b>Good</b> <b>Manufacturing</b> <b>Practice</b> (GMP) {{to ensure}} the quality of the finished product and also demonstrate safety.|$|E
50|$|From 2003 to 2004 grandiose {{reconstruction}} of the manufacturing plant was finished {{in compliance with the}} requirements of <b>Good</b> <b>Manufacturing</b> <b>Practice</b> of the European Union.|$|E
50|$|<b>Good</b> <b>manufacturing</b> <b>practices,</b> {{along with}} <b>good</b> {{agricultural}} practices, good laboratory practices and good clinical practices, are overseen by regulatory {{agencies in the}} United States, Canada, Europe, China, and other countries.|$|R
50|$|In the United States, pectin is GRAS - {{generally}} recognized as safe. In most foods {{it can be}} used according to <b>good</b> <b>manufacturing</b> <b>practices</b> in the levels needed for its application ("quantum satis").|$|R
5000|$|... {{the impact}} of the {{differences}} in Glaxo's <b>good</b> <b>manufacturing</b> <b>practices</b> and health, safety and environmental standards on the comparability of the ranitidine purchased by the appellant with that purchased by the generic companies ...|$|R
50|$|Wockhardt {{received}} a FDA warning letter 25 November 2013 identifying significant violations of current <b>good</b> <b>manufacturing</b> <b>practice</b> for finished pharmaceuticals at the Chikalthana and Waluj facilities.|$|E
50|$|On 30 July 2004, JSC Olainfarm {{obtained}} a <b>Good</b> <b>Manufacturing</b> <b>Practice</b> certificate of compliance. This certificate symbolized {{the start of}} a new period in the Company’s history.|$|E
50|$|When applicable, {{information}} if {{the manufacturing}} site is periodically inspected by certifying authority {{and if the}} manufacturing site complies with <b>Good</b> <b>Manufacturing</b> <b>Practice</b> (GMP) as recommended by WHO.|$|E
50|$|Badly cleaned {{materials}} can transfer remaining bacteria and such {{to the body}} of the jewelry-wearer, so therefore {{it is very important that}} you buy your jewelry from a company with ethical <b>good</b> <b>manufacturing</b> <b>practices.</b>|$|R
30|$|The {{manufacture}} of Geistlich Bio-Graft is {{according to a}} standardized, controlled process and <b>good</b> <b>manufacturing</b> <b>practices</b> (GMPs). Each batch is manufactured and documented according to standard operating procedures, and the entire process has been validated.|$|R
50|$|As {{previously}} mentioned moprolol is currently off the market, most {{likely due to}} the SIMS facility being in violation of US <b>good</b> <b>manufacturing</b> <b>practices.</b> This means that currently there are no sales being brought in by moprolol.|$|R
